ID: ALA5286608

Max Phase: Preclinical

Molecular Formula: C20H22N2O2

Molecular Weight: 322.41

Representations

Canonical SMILES:  C/C=C/Cn1cc(-c2ccc(C(C)(C)O)cc2)c2cc[nH]c2c1=O

Standard InChI:  InChI=1S/C20H22N2O2/c1-4-5-12-22-13-17(16-10-11-21-18(16)19(22)23)14-6-8-15(9-7-14)20(2,3)24/h4-11,13,21,24H,12H2,1-3H3/b5-4+

Standard InChI Key:  HCKOJNDQXGXWSS-SNAWJCMRSA-N

Molecule Features

Natural Product: No

Oral: No

Chemical Probe: No

Parenteral: No

Molecule Type:

Topical: No

First In Class: No

Black Box: No

Chirality: No

Availability: No

Prodrug: No

Properties

Molecular Weight: 322.41

Molecular Weight (Monoisotopic): 322.1681

AlogP: 3.80

#Rotatable Bonds: 4

Polar Surface Area: 58.02

Molecular Species: NEUTRAL

HBA: 3

HBD: 2

#RO5 Violations: 0

HBA (Lipinski): 4

HBD (Lipinski): 2

#RO5 Violations (Lipinski): 0

CX Acidic pKa: 12.62

CX Basic pKa:

CX LogP: 3.03

CX LogD: 3.03

Aromatic Rings: 3

Heavy Atoms: 24

QED Weighted: 0.72

Np Likeness Score: 0.14

References

1. Crawford TD, Vartanian S, Côté A, Bellon S, Duplessis M, Flynn EM, Hewitt M, Huang HR, Kiefer JR, Murray J, Nasveschuk CG, Pardo E, Romero FA, Sandy P, Tang Y, Taylor AM, Tsui V, Wang J, Wang S, Zawadzke L, Albrecht BK, Magnuson SR, Cochran AG, Stokoe D..  (2017)  Inhibition of bromodomain-containing protein 9 for the prevention of epigenetically-defined drug resistance.,  27  (15): [PMID:28606761] [10.1016/j.bmcl.2017.05.063]

Source

Source(1):

• Scientific Literature